Suppression of atopic-like dermatitis by treatment with antibody to lymphocyte function-associated antigen-1 in NC/Nga mouse.
The effect of a blocking-antibody specific for lymphocyte function-associated antigen-1 (LFA-1) was studied in an atopic-like dermatitis model, which was induced by the repeated application of picrylchloride in NC/Nga mice. Prophylactic treatment with anti-LFA-1 monoclonal antibody (mAb), not therapeutic treatment, significantly inhibited the skin severity score and the acanthosis with ulceration and infiltration of mast cells. Furthermore, the serum immunoglobulin E levels and cytokine production (interleukin-4 and interferon-gamma) by splenocytes stimulated with anti-CD3 antibody were also inhibited by treatment with anti-LFA-1 mAb. Our results suggest that LFA-1 plays an important role in the induction phase of the atopic-like dermatitis model.
Ohmura
Tsuyoshi
T
Department of Pharmacology, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd., 3-10-1 Yato, Kawanishi, Japan. ohmura@boehringer-ingelheim.co.jp
Konomi
Ayako
A
Satoh
Yayoi
Y
Hayashi
Toshihiro
T
Tsunenari
Ichiro
I
Kadota
Toshihito
T
Panzenbeck
Maret J
MJ
Satoh
Hisashi
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology*; D008297:Male; D051379:Mice
D000911:Antibodies, Monoclonal; D016169:Lymphocyte Function-Associated Antigen-1; C114320:anti-LFA-1 monoclonal antibody; D007073:Immunoglobulin E